Medicine, the media and monetary interests: the need for transparency and professionalism

---

• 1.
• Busfield W. Melanoma vaccine next year. The Daily 1Telegraph, 19 November 1999: 3.
• 2.
• The Australian Press Council. Adjudication No. 1081. Re: The Daily Telegraph, 19 November, 1999.
• 3.
• Greenblat A. Cancer drug fires up AVT. The Age 20 July 2000: B3; and The Sydney Morning Herald, 20 July 2000: 23.
• 4.
• Moynihan R, Bero L, Ross-Degnan D, et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med 2000; 342: 1645-1650.
• 5.
• Leask J, Chapman S. An attempt to swindle nature: press anti-immunisation reportage 1993-1997. Aust N Z J Public Health 1998; 22: 17-26.
• 6.
• Wills PJ (Chairman). Health and Medical Research Strategic Review. The virtuous cycle -- working together for health and medical research. Canberra: Department of Health and Aged Care, 1999.
• 7.
• Angell M. Is academic medicine for sale? [editorial]. N Engl J Med 2000; 342: 1516-1518.
• 8.
• Weatherall D. Academia and industry: increasingly uneasy bedfellows. Lancet 2000; 355: 1574.
• 9.
• Swedish Society of Medicine. Berzelius Symposium 54 -- Medicine and the Media. 31 August-1 September 2000. Stockholm.
• 10.
• Kolata G. Hope in the lab -- A special report: A cautious awe greets drugs that eradicate tumors in mice. New York Times, 3 May 1998.
• 11.
• Jacobs P. Biotech stocks ride roller coaster of publicity. Los Angeles Times 21 March 1999.
• 12.
• Ashraf H. British Medical Journal apologises to biotech company [news]. Lancet 2000; 355: 2139.
• 13.
• A Current Affair, June 14, 2000.
• 14.
• Summary of evidence about effectiveness of zanamivir. National Institute for Clinical Excellence, UK, 1999. <http://www.nice.org.uk/nice-web/Article.asp?a=427> Accessed 14 November 2000.
• 15.
• Relenza [US Food and Drug Administration consumer drug information]. <http://www.fda.gov/cder/ consumerinfo/druginfo/relenza.htm> Accessed 14 November 2000.
• 16.
• The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
• 17.
• Moynihan R. Too much medicine? Sydney: ABC Books, 1998: 8.
• 18.
• Wazana A. Physicians and the pharmaceutical industry. JAMA 2000; 283: 373-380.
• 19.
• Sweet M. Medicines and the media; a journalist's view. Aust Prescriber 2000; 23: 70-71.
• 20.
• The Royal Australasian College of Physicians. Ethical guidelines in the relationship between physicians and the pharmaceutical industry. Sydney: RACP, 2000.
• 21.
• Shalala D. Protecting research subjects: what must be done? N Engl J Med 2000; 343: 808-810.
• 22.
• Greenberg DS. Stricter regulation proposed for US gene therapy trials [news]. Lancet 2000; 355: 1977.
• 23.
• Commercial Radio Inquiry. Report of the Australian Broadcasting Authority hearing into Radio 2UE Sydney Pty Limited, Sydney: ABA, 2000.
• 24.
• Sweet M. Journalist, heal thyself. Walkley Magazine, August 1999: 15.
• 25.
• Oxman A. Evidence-based medicine and medical journalism. Presentation to Berzelius Symposium 54 -- Medicine and the Media. 31 August-1 September 2000. Stockholm.
• 26.
• Irwig L. University of Sydney continuing education courses on evaluating health studies.
• 27.
• Levi R. Medical journalism: exposing fact, fiction, fraud. Studentlitteratur 2000 Stockholm. <www.studentlitteratur.se> Accessed 14 November 2000.
• 28.
• Bengtsson H. The roles of the Medical Journalist. Presentation to Berzelius Symposium 54 -- Medicine and the Media. 31 August-1 September 2000. Stockholm.